仙后座
威斯康星州简斯维尔
OVERVIEW
A purpose-built n.c.a. Lu-177 production facility
Some cancers stop responding to treatment. Lutetium-177, a therapeutic radioisotope, gives
doctors another option. Paired with a molecule that seeks out cancer cells, it delivers radiation directly to the tumor while limiting damage to healthy tissue. There are two approved Lu-177 therapies now in use and more than 200 active clinical trials underway.
Cassiopeia is where we make Ilumira, our non-carrier-added Lu-177, under the cGMP standards the FDA and EMA require. The facility is designed to support roughly 100,000 doses a year.
We control every step, from securing enriched ytterbium-176, through final shipment, and our process recovers more than 95% of ytterbium during production.
主要设施数据
主要产品
Ilumira – Lutetium177 chloride
状态
Production at commercial volume
区别
Global source of llumira
System Type
Radiochemical & pharmaceutical manufacturing
Energy Output
~100,000 doses/year
Chemists once called lutetium “cassiopeium.” We chose the name Cassiopeia for the building where we make our n.c.a. Lu-177, delivered weekly worldwide.
VIDEO TOUR
Tour Cassiopeia
Step inside Cassiopeia. See where llumira is made, from start to finish.
图片库
See inside Cassiopeia
Inside Cassiopeia: the rooms, equipment and people behind every vial of
llumira.
WHAT HAPPENS HERE
Capabilities & specs
n.c.a. Lu-177 production
Cassiopeia produces llumira, that’s used in cancer treatments worldwide.
Radiochemical processing
We separate the n.c.a. Lu-177 and purify it to 99.9% radionuclidic purity, then fill and
package it for shipment worldwide.
cGMP manufacturing
Every batch is made to current Good Manufacturing Practice standards.
Quality & regulatory systems
Cassiopeia operates under an accepted FDA Drug Master File and holds European Marketing Authorization for llumira.
Scalable capacity
Capacity today is roughly 100,000 doses a year.
Global distribution
llumira ships from Cassiopeia to CDMOs, researchers, and providers on six continents.
NEWS FEED
Cassiopeia in the news
设施
一个平台，多个设施
在我们各设施中，相同的核心能力支撑着聚变系统研发、中子测试、医用同位素生产、放射化学以及商业运营。
威斯康星州简斯维尔
项目建成后，我们预计“Chrysalis”将成为全球规模最大的钼-99（Mo-99）医用同位素生产设施之一。该设施将利用聚变驱动技术在美国生产钼-99，从而填补海外核反应堆退役后留下的供应缺口，并缓解医院面临的实际短缺问题。
威斯康星州简斯维尔
Cassiopeia 公司生产 Ilumira——这是一种用于癌症治疗的、不含载体添加物的镥-177 制剂。Ilumira 始终如一的高品质，为全球各地的治疗方案提供了精准、可靠的给药保障。
威斯康星州菲奇堡
赫利奥波利斯是位于威斯康星州菲奇堡的、占地47,500平方英尺的生产基地。在这里，我们设计、制造并测试整套首创的聚变系统。无论是电磁铁、离子源还是氚处理设备——只要是尚未存在的设备，我们都会在这里制造出来。
威斯康星州简斯维尔
一号楼运行着我们的辐射效应测试系统，其运行速度约为每秒46万亿次聚变反应。航空航天和国防领域的客户在此测试其电子设备在辐射环境下的耐受性，而我们的放射化学家则致力于开发支撑同位素分离和燃料回收的分离科学。
马萨诸塞州北比勒里卡
我们的同位素配送中心生产并分销单光子发射计算机断层扫描（SPECT）显像剂，这些显像剂每年为北美各地的医院和影像中心提供数百万例心脏、肺部、甲状腺及其他领域的诊断检查提供支持。